References
- Borish, L.C. and Steinke, J.W. (2003). 2. Cytokines and chemokines. J Allergy Clin Immunol 111, S460-475 https://doi.org/10.1067/mai.2003.108
- Brown, J.A., Dorfman, D.M., Ma, F.R., Sullivan, E.L., Munoz, O., Wood, C.R., Greenfield, E.A. and Freeman, G.J. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170, 1257-1266 https://doi.org/10.4049/jimmunol.170.3.1257
- Casanovas Taltavull, T. (2004). Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant Proc 36, 291S-294S https://doi.org/10.1016/j.transproceed.2003.12.032
- Girlanda, R., Rela, M., Williams, R., O'Grady, J.G. and Heaton, N.D. (2005). Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 37, 1708- 1709 https://doi.org/10.1016/j.transproceed.2005.03.070
- Heathcote, E.J. (2000). Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31, 1005-1013 https://doi.org/10.1053/he.2000.5984
- Hwang, K.W., Sweatt, W.B., Mashayekhi, M., Palucki, D.A., Sattar, H., Chuang, E. and Alegre, M.L. (2004). Transgenic expression of CTLA-4 controls lymphoproliferation in IL-2- deficient mice. J Immunol 173, 5415-5424 https://doi.org/10.4049/jimmunol.173.9.5415
- Ikegami, T. and Matsuzaki, Y. (2008). Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res 38, 123-131
- Kelso, A. and Gough, N.M. (1989). Differential inhibition by cyclosporin a reveals two pathways for activation of lymphokine synthesis in T cells. Growth Factors 1, 165-177 https://doi.org/10.3109/08977198909029126
- Liu, L., Sakaguchi, T., Cui, X., Shirai, Y., Nishimaki, T. and Hatakeyama, K. (2002). Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats. Am J Chin Med 30, 119-126 https://doi.org/10.1142/S0192415X02000132
- Loke, P. and Allison, J.P. (2003). PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100, 5336-5341 https://doi.org/10.1073/pnas.0931259100
- Maraskovsky, E., Chen, W.F. and Shortman, K. (1989). IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143, 1210-1214
- Persson, H., Friman, S., Schersten, T., Svanvik, J. and Karlberg, I. (1990). Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 336, 52-53
- Poupon, R.E., Lindor, K.D., Cauch-Dudek, K., Dickson, E.R., Poupon, R. and Heathcote, E.J. (1997). Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113, 884-890 https://doi.org/10.1016/S0016-5085(97)70183-5
- Ritter, M., Hohenberger, K., Alter, P., Herzum, M., Tebbe, J. and Maisch, M. (2005). Caffeine inhibits cytokine expression in lymphocytes. Cytokine 30, 177-181 https://doi.org/10.1016/j.cyto.2004.12.013
- Rubin, R.H. (1987). The compromised host as sentinel chicken. N Engl J Med 317, 1151-1153 https://doi.org/10.1056/NEJM198710293171809
- Tanaka, H., Makino, Y., Miura, T., Hirano, F., Okamoto, K., Komura, K., Sato, Y. and Makino, I. (1996). Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 156, 1601-1608
- Tomida, S., Abei, M., Yamaguchi, T., Matsuzaki, Y., Shoda, J., Tanaka, N. and Osuga, T. (1999). Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 30, 6-13 https://doi.org/10.1002/hep.510300108
- Wahl, P., Schoop, R., Bilic, G., Neuweiler, J., Le Hir, M., Yoshinaga, S.K. and Wuthrich, R.P. (2002). Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 13, 1517-1526 https://doi.org/10.1097/01.ASN.0000017901.77985F
- Wall, W.J. and Ghent, C.N. (1995). Immunosuppression in liver transplantation: monitoring, dose adjustment, reduction, and withdrawal. Liver Transpl Surg 1, 3-10